Oyster Point Pharma, Inc.
OYSTDelisted Jan 3, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001720725
Oyster Point Pharma, Inc. was delisted on Jan 3, 2023; its insiders filed their last Form 4 on Jan 5, 2023; 53 institutions reported holding it in 13F filings for Q4 2022, worth $189.4M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:04 PM ET
Revenue flow, FY2021
Where the revenue went in FY2021, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2021: $100.7M (410.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2022 | Feb 18, 2021 | Feb 27, 2020 |
| Revenue | $24.5M | – | – |
| Cost of revenue | $1.52M | – | – |
| Operating expenses | $119.7M | $71.0M | $47.3M |
| Research and development | $24.2M | $39.8M | $33.6M |
| Selling, general and administrative | $40.8M | $31.2M | $13.7M |
| Operating income | -$96.7M | -$71.0M | -$47.3M |
| Interest expense | $3.73M | – | – |
| Income tax | $0 | $0 | $0 |
| Net income | -$100.7M | -$70.5M | -$45.7M |
| EPS, basic | $-3.87 | – | – |
| EPS, diluted | $-3.87 | – | – |
| Weighted shares, basic | 26.0M | – | – |
| Weighted shares, diluted | 26.0M | – | – |
| Margins and growth | |||
| Operating margin | -393.9% | – | – |
| Net margin | -410.2% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2022 | Feb 18, 2021 | Feb 27, 2020 |
| Cash and equivalents | $193.4M | $192.6M | $139.1M |
| Accounts receivable | $6.66M | – | – |
| Inventory | $6.09M | – | – |
| Total current assets | $215.3M | $196.4M | $142.2M |
| Property, plant and equipment | $2.50M | $804.0K | $181.0K |
| Total assets | $222.6M | $197.9M | $143.2M |
| Accounts payable | $6.50M | $2.28M | $500.0K |
| Total current liabilities | $28.8M | $11.0M | $5.40M |
| Long-term debt | $89.8M | – | – |
| Total liabilities | $123.1M | $11.3M | $5.91M |
| Shareholders' equity | $99.5M | $186.7M | $137.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2022 | Feb 18, 2021 | Feb 27, 2020 |
| Operating cash flow | -$89.4M | -$58.4M | -$40.8M |
| Capital expenditures | $1.49M | $700.0K | $200.0K |
| Free cash flow | -$90.9M | -$59.1M | -$41.0M |
| Depreciation and amortization | $141.0K | $77.0K | $19.0K |
| Stock-based compensation | $11.9M | $6.97M | $3.27M |
| Investing cash flow | -$1.49M | -$700.0K | -$200.0K |
| Financing cash flow | $91.6M | $112.5M | $175.0M |
| Net change in cash | $787.0K | $53.4M | $134.0M |
| Ratio | |||
| Stock-based compensation, % of revenue | 48.7% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 4, 2022 | 26.8M | +2.6% | SEC |
| Aug 5, 2022 | 26.8M | +3.1% | SEC |
| Apr 29, 2022 | 26.7M | +2.7% | SEC |
| Feb 16, 2022 | 26.6M | +2.8% | SEC |
| Oct 29, 2021 | 26.2M | +1.1% | SEC |
| Jul 30, 2021 | 26.0M | +1.0% | SEC |
| Apr 30, 2021 | 26.0M | +21.5% | SEC |
| Feb 1, 2021 | 25.9M | +21.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.